Endo Manufacturing Co., Ltd.
Financial Summary for the Six Months Ended December 2026 (Interim) [Japanese Standards] (Consolidated)
For the six months ended December 2026, consolidated net sales were 10.09 billion yen, up 9.5% YoY. Operating income declined by 593.7 million yen, ordinary income was 635.8 million yen, and net income attributable to owners of the parent stood at 384.3 million yen, a decrease. The Fine Process segment achieved net sales of 5.046 billion yen with solid demand similar to the prior year, though profits were pressured by higher raw material costs. The Metal segment net sales were 5.043 billion yen with a 4.3% increase in profit. There were no changes to the full-year guidance. In July 2026, a business combination to acquire Medivation, Inc. was announced to strengthen the medical device business base and improve capital efficiency.
Key Figures
- Net sales: 10,090,377千円（YoY 9.5% increase）
- Operating income: 593,657千円（YoY △16.0% decrease）
- Net income attributable to owners of the parent (interim): 384,320千円（YoY △31.2% decrease）
AI要約
Overview of performance
For the second quarter of the current fiscal year, consolidated net sales were about 10.09 billion yen, an increase year over year. However, operating income, ordinary income, and net income declined sharply. The Fine Process segment saw strong orders for new products, but profits were pressured by rising material costs and a weaker yen. The Metal segment saw an increase in operating income year over year due to steady orders and efficiency improvements. There is no change to the initial full-year forecast.
M&A-related outlook
In July 2026, it was resolved to acquire and make Medivation, Inc. a subsidiary, with the acquisition date on July 13. Through the combined effects, the company aims to strengthen the medical device business and improve capital efficiency. The group will continue to pursue growth opportunities across the organization toward achieving the mid-term plan.
Endo Manufacturing Co., Ltd.
Company overview · Stock price · Financial data · All IR
